Understanding genetic changes in high-risk ovarian cancer
Official title: Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11083078 · Data updated 2026-11-12
This study is looking at how certain genetic changes happen early on in high-grade serous ovarian cancer, especially for those with inherited BRCA1 or BRCA2 mutations, to find markers that could help predict if a pre-cancer condition will turn into invasive cancer, ultimately aiming to improve treatment options for patients at higher risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 6, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $734,548 |
| NIH project number | 5R01CA281928-03 |
| Project ID | NIH-11083078 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with BRCA1 or BRCA2 mutations who are at high risk for ovarian cancer.
✕Less likely to help
Patients without genetic predispositions to ovarian cancer or those who do not carry BRCA1/BRCA2 mutations may not benefit from this research.
What this research studies
This research investigates the early genetic changes that occur in high-grade serous ovarian cancer (HGSC), particularly in patients at increased risk due to inherited BRCA1/BRCA2 mutations. The study focuses on identifying biomarkers of genomic instability, which may help predict the progression from pre-invasive conditions to invasive cancer. By analyzing patient samples, researchers aim to quantify specific markers associated with chromosomal instability, potentially leading to improved treatment strategies for high-risk individuals. The goal is to enhance therapeutic decisions and outcomes for patients who have undergone preventive surgeries.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and treatment options for patients at high risk of developing ovarian cancer.
How similar studies have gone: Previous research has shown promising results in identifying biomarkers for cancer progression, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Shah, Sohrab P — Sloan-Kettering Inst Can Research
- Study coordinator: Shah, Sohrab P
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.